Prevalence of new coronavirus infection COVID-19 in patients undergoing pulmonary thromboendarterectomy (data from a single-center registry)

Aim. To assess the prevalence and clinical and functional features of a new coronavirus infection (COVID-19) in patients who underwent pulmonary thromboendarterectomy (PTE) using data from a single-center registry. Methods. This study included 127 patients with chronic thromboembolic pulmonary hypertension who underwent PTE from January 2016 to March 2020 and were included in a follow-up group. The follow-up after surgery was 6 or more months. The prevalence of COVID-19 and clinical and functional properties of the cardiorespiratory system were assessed in the study group. Results. The average follow-up period after PTE in the study group was 2.5 ± 0.9 years. 14 (11%) deaths not associated with COVID-19 were reported during this period. 5 cases of COVID-19 were detected among the remaining 113 patients. In one case, the infection was asymptomatic, while other patients had the typical clinical symptoms and developed bilateral polysegmental pneumonia. No patients required mechanical ventilation or died of COVID-19. All patients who underwent PTE were compliant with anticoagulation therapy and PAH-specific therapy for residual pulmonary hypertension. No adjustment of PAH-specific and anticoagulation therapy was required during COVID-19. Conclusion. The prevalence of COVID-19 in patients who underwent PTE was 4.4%, no deaths were recorded. Outpatient follow-up and timely informing of patients undergoing PTE allow keeping the COVID-19 morbidity and mortality in the studied group at the general population level. Evaluation of the impact of chronic anticoagulants and PAH-specific therapy on the outcome of COVID-19 deserves further research.

1. Avdeev S.N., Tsareva N.N., Merzhoeva Z.M. et al. [Practical guidance for oxygen treatment and respiratory support of patients with COVID-19 infection before admission to intensive care unit]. Pul’monologiya. 2020; 30 (2): 151–163. DOI: 10.18093/0869-0189-2020-30-2-151-163. (in Russian).

2. World Health Organization. Coronavirus Disease 2019 (COVID-19). Situation Report – 189. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200727-covid-19-sitrep-189.pdf?sfvrsn=b93a6913_2 [Accessed: July 27, 2020].

3. Ministry of Health of the Russian Federation. [The Temporary Guidelines: Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)]. Version 9 (October 26, 2020). Availble at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf?1603730062 [Assessed: 20.11.20] (in Russian).

4. Bubnova M.G., Aronov D.M. [COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation]. Pul’monologiya. 2020; 30 (5): 688–699. DOI: 10.18093/0869-0189-2020-30-5-688-699. (in Russian).

5. Nuche J., Segura de la Cal T., Jiménez López Guarch C. et al. Effect of coronavirus disease 2019 in pulmonary circulation. The particular scenario of precapillary pulmonary hypertension. Diagnostics. 2020; 10 (8): 548. DOI: 10.3390/diagnostics10080548.

6. Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J. Am. Coll. Cardiol. 2020; 75 (18): 2352–2371. DOI: 10.1016/j.jacc.2020.03.031.

7. Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiology. 2020; 5 (7): 811–818. DOI: 10.1001/jamacardio.2020.1017.

8. Danzi G.B., Loffi M., Galeazzi G., Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur. Heart J. 2020; 41 (19): 1858. DOI: 10.1093/eurheartj/ehaa254.

9. Magrone T., Magrone M., Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target – a perspective. Endocr. Metab. Immune Disord. Drug Targets. 2020; 20 (6): 807–811. DOI: 10.2174/1871530320666200427112902.

10. Humbert M., Guignabert C., Bonnet S. et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J. 2019; 53 (1): 1801887. DOI: 10.1183/13993003.01887-2018.

11. Harder E.M., Small A.M., Fares W.H. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir. Med. 2020; 161: 105850. DOI: 10.1016/j.rmed.2019.105850.

12. Chazova I.E., Martynyuk T.V. [Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 2)]. Terapevticheskiy arkhiv. 2016; 88 (10): 63–73. DOI: 10.17116/terarkh201688663-73. (in Russian).

13. Galie N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Respir. J. 2015; 46 (6): 1855–1856. DOI: 10.1183/13993003.51032-2015.

14. Horn E.M., Chakinala M., Oudiz R. et al. Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm. Circ. 2020; 10 (2): 2045894020922799. DOI: 10.1177/2045894020922799.

15. Segura de la Cal T., Nuche J., Jiménez López-Guarch C. et al. Unexpected favourable course of Coronavirus Disease 2019 in chronic thromboembolic pulmonary hypertension patients. Arch. Bronconeumol. 2020; 56 (11): 749–752. DOI: 10.1016/j.arbres.2020.06.004 (in English, Spanish).

16. Sardu C., Gambardella J., Morelli M.B. et al. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J. Clin. Med. 2020; 9 (5): 1417. DOI: 10.3390/jcm9051417.

17. Smeda M., Chlopicki S. Endothelial barrier integrity in COVID-19-dependent hyperinflammation: does the protective facet of platelet function matter? Cardiovasc. Res. 2020; 116 (10): e118–121. DOI: 10.1093/cvr/cvaa190.

18. Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. 2020; 41 (19): 1798–1800. DOI: 10.1093/eurheartj/ehaa231.

19. Cooper L.T. Jr. Myocarditis. N. Engl. J. Med. 2009; 360 (15): 1526-1538. DOI: 10.1056/NEJMra0800028.

20. Levy J., Léotard A., Lawrence C. et al. A model for a ventilator-weaning and early rehabilitation unit to deal with post-ICU impairments following severe COVID-19. Ann. Phys. Rehabil. Med. 2020; 63 (4): 376–378. DOI: 10.1016/j.rehab.2020.04.002.

21. Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8 (5): 475–481. DOI: 10.1016/S2213-2600(20)30079-5.

22. Carfì A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324 (6): 603–605. DOI: 10.1001/jama.2020.12603.

23. Mo X., Jian W., Su Z. et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur. Respir. J. 2020; 55 (6): 2001217. DOI: 10.1183/13993003.01217-2020.

24. Patelli G., Paganoni S., Besana F. et al. Preliminary detection of lung hypoperfusion in discharged COVID-19 patients during recovery. Eur. J. Radiol. 2020; 129: 109121. DOI: 10.1016/j.ejrad.2020.109121.

25. Becker R.C. COVID-19 update: COVID-19-associated coagulopathy. J. Thrombosis Thrombolysis. 2020; 50 (1): 54–67. DOI: 10.1007/s11239-020-02134-3.